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| INTRODUCTION
Von Willebrand disease type 2M (VWD2M) is an autosomal dominant bleeding disorder usually described by laboratory phenotype of VWF:RCo/VWF:Ag<0.6 and normal multimeric profile. Most cases show defective platelet glycoprotein Ibα (GPIbα) binding, revealed by low VWF:RCo. Although VWF:CB/VWF:Ag>0.6 are frequent, abnormal ratios are also described.
1,2 Mutations responsible for VWD2M
are mainly clustered in the VWF-A1 domain.
We describe a patient with a severe bleeding score and VWD2M laboratory phenotype, in which a compound heterozygous state was detected, and his behavior was compared to Caucasian VWD2M controls (heterozygous and homozygous) with mutations in the VWF-A1
domain.
| MATERIALS AND METHODS

| Subjects and controls
The proband is a Caucasian 12-year-old boy. He was referred due to epistaxis requiring tamponades, bleeding after tooth eruption and extraction, easy bruising, gum bleeding, and bleeding in the central nervous system. After this last episode, he started prophylactic treatment with VWF-FVIII concentrates (1000 U, twice a week). The bleeding score was calculated according to the ISTH bleeding assessment tool (ISTH-BAT). 3 His 30-year-old mother had epistaxis, easy bruising, gum bleeding, and abnormal menstrual score according to the Pictorial Bleeding Assessment Chart 4 (PBAC = 192, nv < 185). His 40-year-old father and his sister did not show bleeding symptoms. The parents were non-consanguineous. They gave their written informed consent for the study, in accordance with the declaration of Helsinki.
Moreover, approval from the Ethics Committee of the Academia Nacional de Medicina, Buenos Aires, Argentina, was obtained.
Thirteen VWD2M patients, with desmopressin (DDAVP) challenge test, were selected as controls. They carry either homozygous: p.Arg1374Cys (n = 1), or heterozygous mutations: p.Arg1334Gln (n = 1), p.Arg1374Leu (n = 1), p.Arg1374Cys (n = 7), p.Ala1437Thr (n = 2), p.Thr1468Ile (n = 1).
| Sample preparation
Peripheral venous blood was drawn in 3.13% sodium citrate for clotting tests and in 2% EDTA (disodium ethylenediaminetetraacetate dihydrate)
for DNA analysis. An anticoagulant with anti-proteases (3.8% sodium citrate; 60 mmol/L N-ethylmaleimide, 50 mmol/L EDTA, and 2000 KIU/ mL aprotinine), was used to collect samples for multimer analysis.
| Laboratory methods
The following tests were performed: blood platelet count (Plt); bleed- 
| Biologic response to DDAVP
Blood samples for DDAVP challenge test were obtained before and Proband's behavior was compared to controls (11 heterozygous VWD2M, mean age of 24.4 ± 14.7-year-old, and 1 homozygous patient, aged 7 years); 36% of them had O blood group. BS and BT were lower in heterozygous controls (BS: 4.8 ± 3.5; BT: 7.4 ± 1.7 minutes) than in the homozygous control (BS: 9; BT: 8 minutes).
| Genotypic analysis
Genomic DNA was extracted from peripheral blood using standard methods. Exons 17, 26 to 31, and 52 of VWF gene were analyzed using polymerase chain reaction technique (PCR), and primers designed in our laboratory. Both forward and reverse strands were sequenced by automated sequencing technology (ABI Prism 310 Genetic Analyzer;
Applied Biosystems, Foster City, CA, USA). One-hundred random healthy controls were also screened.
Allele-specific PCR method (AS-PCR) was developed to establish if mutations were located in cis or trans position. To achieve this goal, an asymmetric PCR method was optimized. This procedure produced ssDNA fragments of 902 base-pairs in a single step when primer pairs were used at a 10:1 molar ratio in the presence of genomic DNA.
AS-forward primer (AS-1426-Fw-mut) was designed by using appropriate software to allow the PCR amplification only if the nucleotide at the 3′-end of the primer complemented the base at the c.4276
Essentials
• Compound heterozygosity causes a VWD2M phenotype in a child with severe bleeding symptoms.
• p.P1648fs*45 changes the folding of A2 domain altering VWF binding to GPIbα and type VI collagen.
• p.P1648fs*45 was considered as an apparent de novo mutation; AS-PCR revealed paternal mosaicism.
• Bleeding score and DDAVP's response were worse than those seen in VWD2M heterozygous controls.
position in the C1426-DNA sample. The PCR reaction tube contained 
| In silico, alignment, and modeling analysis
The in silico analysis of changes was performed using PolyPhen-2 
| Statistical analysis
Continuous variables were expressed using mean (X), standard deviation (SD), and minimum (min) and maximum (max) values (ranges).
| RESULTS AND DISCUSSION
The phenotypic and the molecular data of the proband and his parents are display in Other situations in which a second mutation and the O blood group reinforces the decrease of FVIII:C and VWF have been reported. 19, 20 VWF binds types I and III collagen via the VWF-A3 and VWF-A1
domains, but it binds sub-endothelial type VI collagen exclusively via the VWF-A1 domain
21
; the latter seems to be important in the VWFplatelet binding under low shear. 22 Reduced binding to type VI collagen has been reported in VWD2M patients in the presence of four mutations located in VWF-A1 domain. 23 Fidalgo et al. Compound heterozygosity would result in a severe clinical phenotype, similar to a homozygous VWD2M behavior, despite it is not the case. Heterozygous p.Arg1426Cys in proband's mother suggests possible type 1 VWD, and p.Pro1648fs*45 has been described as responsible for type 1 VWD. Therefore, there are some inconsistencies between proband's genotype and phenotype. The bleeding history and the VWD2M laboratory phenotype, including the poor response to DDAVP, seen in the proband would be the result of a synergistic effect. We believe that the combination of the two heterozygous mutations could modify the expression of VWF and result in a defective phenotype enhancer, as was described for other mutations.
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